Non-specific cross-reacting antigen (NCA) in individual maturation stages of myelocytic cell series

Rhenium 188–labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study

“…[25][26][27] The CD66 antigen is expressed at a high density (2 ϫ 10 5 molecules per cell) on normal myelopoietic cells from the promyelocyte onward but not on AML blasts. [28][29][30][31] Aberrant expression is found on a significant fraction of CD10 ϩ acute lymphoblastic leukemia (ALL) blasts. 31,32 The CD66 molecule is neither internalized nor shed.…”

Relationship between myelomonocytic, myeloid and nonspecific cross-reacting (NCA) antigens during myelocytic cell differentiation

“…The other important antibody detecting myelomonocytic cell surface antigen M2 is VIM-2. A valuable marker of granulocytic differentiation is also nonspecific cross-reacting antigen (NCA) (Burtin et al, 1979(Burtin et al, ,1980Heumann et al, 1979;Wahren et al, 1980;Noworolska et al, 1985). To our knowledge no data are available concerning the relationship and sequence of appearance of the antigens detectable by VIM-2 and VIM-D5 monoclonal antibodies and NCA expression.…”

“…The distribution of M2 and FAL determinants was studied on living cells only because the available monoclonal antibodies were directed against surface antigens (Majdic et al, 1984;Gooi et al, 1985) and NCA expression on living and fixed cells because this antigen could be easily detected after fixation (Noworolska et al, 1985). According to other data (Majdic et al, 1984;Pessano et al, 1984) a leukaemia was classified as antigen positive if > 15% of cells were reactive by immunofluorescence after treatment with a particular monoclonal antibody.…”

Radioimmunotherapy-based conditioning for hematopoietic cell transplantation in children with malignant and nonmalignant diseases

“…The anti-CD66 monoclonal antibody is a murine IgG1 antibody; CD66 is expressed at a high density on normal myelopoietic cells from the promyelocyte onward up to mature granulocytes. [17][18][19] The antibody has been explored for use in radioimmunotherapy in phase 1 or 2 studies in adults by labeling with rhenium-188 ( 188 Re), which is a The online version of this article contains a data supplement.…”